Dr. Tiffany Nicole Tanaka, MD

Dr. Tanaka practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Tanaka's NPI, 1407159726, was assigned on December 8, 2010. Dr. Tanaka graduated from John A. Burns School of Medicine in 2010. Dr. Tanaka's California license number on file is A119740.

Dr. Tanaka's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Tanaka's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Tanaka is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Tanaka to 1 more group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tanaka practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tanaka's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tanaka is board certified in hematology by the American Board of Internal Medicine. Dr. Tanaka has a license on file in California.

Dmand AI lists chronic anemia, chronic leukemia, lymphoma, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Tanaka treats.

CMS data shows 522 Medicare services from Dr. Tanaka across 5 procedure codes in 2024, for 125 Medicare patients. Medicare paid $47,429 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 125 Medicare patients who saw Dr. Tanaka in 2024. The largest group is 65 to 74, with 51 patients. 72% of them have high blood pressure, and 67% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tanaka's median patient age at 64, with 47% women.

In 2024, Dr. Tanaka wrote 604 Medicare Part D claims for 73 patients. 65% of them were for generic drugs. CMS names the drug for 410 of them, across 19 drugs with 11 or more claims each, at $1,433,463 in total drug cost. In 2023, CMS named 225 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Tanaka for performance year 2024, reported as part of a group. Dr. Tanaka accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tanaka as offering telehealth.

Dmand AI links 12 papers to Dr. Tanaka, published from 2017 to 2022. 2020 was the busiest year, with 3. The most frequent topics are Myelodysplastic Syndromes, Dioxygenases and DNA-Binding Proteins. Dr. Tanaka has published most often in Blood Adv. Dr. Tanaka's most frequent co-authors are Rafael Bejar, MD, PhD, Benjamin Djulbegovic, MD and Namrata I. Peswani, MD.

Dmand AI links Dr. Tanaka to 1 clinical trial. Conditions studied include Myelodysplastic Syndromes and Bone Marrow Diseases.

CMS Open Payments shows 35 general payments to Dr. Tanaka from 10 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 83% of the total. Bristol-Myers Squibb Company paid the most, $10,623.

Dr. Tanaka graduated from John A. Burns School of Medicine in 2010.

Dr. Tanaka is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.